FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598225231> ?p ?o ?g. }

• W2598225231 abstract "e14087 Background: Immunotherapy in real-life, unselected patients with metastatic colorectal cancer (mCRC) was analyzed retrospectively at a single center in Austria. Methods: We have treated 137 mCRC patients with at least one antibody containing therapy since 2004 at our center based at data available at that time and patient eligibility. Results: Most mCRC patients were between 55 and 75 years old. The KRAS mutation testing performed routinely from 2008 onwards shows a distribution of 55 % wildtype (wt) and 45% mutant (mut) KRAS. Median overall survival (OS) was 24 months (n=82) with a trend towards greater benefit for KRAS wt patients compared to KRAS mut (26.8 vs. 20.9 months, respectively). Most patients received between 3 and 5 treatment lines. 40% of patients were treated with 5 therapies and 8% reached treatment line 8. The median OS correlated with the number of therapy lines. Chemotherapy alone regimens are decreasing constantly due to the establishment of biomarker analysis based treatment decisions and the increase in available antibodies for immunotherapy in mCRC. Based on direct positive experience with various antibodies, we were successfully treating patients repeatedly with the same antibodies in non-consecutive treatment lines. 75.7% of all patients treated with Cetuximab received the antibody only once during 3.8 therapy lines. 13% of patients who obtained the agent in two lines received on average 5.7 treatment lines resulting in improved OS. This was even more prominent in 8.5% patients receiving Cetuximab in 3 lines with a trend towards further OS benefit. These data describe that multiple applications of the same antibody is not only feasible but also very effective. Conclusions: By taping the full potential of treatment options, optimizing their usage and expanding the number of treatment lines we could achieve a median OS in real-life patients similar to that previously described in large phase III studies. Our analysis describes the following key factors for reproducing clinical benefits reported in large trials: biomarker assessment, early and if possible multiple applications of available therapeutic antibodies, treatment until progression and use of supportive therapy to alleviate possible toxicities." @default.
• W2598225231 created "2017-04-07" @default.
• W2598225231 creator A5008162226 @default.
• W2598225231 creator A5018918798 @default.
• W2598225231 creator A5030474569 @default.
• W2598225231 creator A5052112147 @default.
• W2598225231 creator A5055066092 @default.
• W2598225231 creator A5064282075 @default.
• W2598225231 creator A5073257587 @default.
• W2598225231 creator A5085791444 @default.
• W2598225231 creator A5087984311 @default.
• W2598225231 creator A5089477351 @default.
• W2598225231 date "2012-05-20" @default.
• W2598225231 modified "2023-10-01" @default.
• W2598225231 title "Single center analysis of immunotherapy in mCRC patients." @default.
• W2598225231 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e14087" @default.
• W2598225231 hasPublicationYear "2012" @default.
• W2598225231 type Work @default.
• W2598225231 sameAs 2598225231 @default.
• W2598225231 citedByCount "0" @default.
• W2598225231 crossrefType "journal-article" @default.
• W2598225231 hasAuthorship W2598225231A5008162226 @default.
• W2598225231 hasAuthorship W2598225231A5018918798 @default.
• W2598225231 hasAuthorship W2598225231A5030474569 @default.
• W2598225231 hasAuthorship W2598225231A5052112147 @default.
• W2598225231 hasAuthorship W2598225231A5055066092 @default.
• W2598225231 hasAuthorship W2598225231A5064282075 @default.
• W2598225231 hasAuthorship W2598225231A5073257587 @default.
• W2598225231 hasAuthorship W2598225231A5085791444 @default.
• W2598225231 hasAuthorship W2598225231A5087984311 @default.
• W2598225231 hasAuthorship W2598225231A5089477351 @default.
• W2598225231 hasConcept C121608353 @default.
• W2598225231 hasConcept C126322002 @default.
• W2598225231 hasConcept C143998085 @default.
• W2598225231 hasConcept C2777701055 @default.
• W2598225231 hasConcept C71924100 @default.
• W2598225231 hasConceptScore W2598225231C121608353 @default.
• W2598225231 hasConceptScore W2598225231C126322002 @default.
• W2598225231 hasConceptScore W2598225231C143998085 @default.
• W2598225231 hasConceptScore W2598225231C2777701055 @default.
• W2598225231 hasConceptScore W2598225231C71924100 @default.
• W2598225231 hasLocation W25982252311 @default.
• W2598225231 hasOpenAccess W2598225231 @default.
• W2598225231 hasPrimaryLocation W25982252311 @default.
• W2598225231 hasRelatedWork W1985611023 @default.
• W2598225231 hasRelatedWork W2049331029 @default.
• W2598225231 hasRelatedWork W2164661093 @default.
• W2598225231 hasRelatedWork W2165180460 @default.
• W2598225231 hasRelatedWork W2255897075 @default.
• W2598225231 hasRelatedWork W2277248114 @default.
• W2598225231 hasRelatedWork W2539314953 @default.
• W2598225231 hasRelatedWork W2588776695 @default.
• W2598225231 hasRelatedWork W2590280289 @default.
• W2598225231 hasRelatedWork W2760029312 @default.
• W2598225231 hasRelatedWork W2889573830 @default.
• W2598225231 hasRelatedWork W2890631345 @default.
• W2598225231 hasRelatedWork W2913776265 @default.
• W2598225231 hasRelatedWork W2921123888 @default.
• W2598225231 hasRelatedWork W2964650870 @default.
• W2598225231 hasRelatedWork W2967754634 @default.
• W2598225231 hasRelatedWork W2968298370 @default.
• W2598225231 hasRelatedWork W3004481566 @default.
• W2598225231 hasRelatedWork W3029741075 @default.
• W2598225231 hasRelatedWork W3091769666 @default.
• W2598225231 isParatext "false" @default.
• W2598225231 isRetracted "false" @default.
• W2598225231 magId "2598225231" @default.
• W2598225231 workType "article" @default.